A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Launched by ELI LILLY AND COMPANY · May 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called LY4170156 to see if it is safe and effective for people with advanced solid tumors, such as certain types of ovarian, endometrial, cervical, lung, breast, pancreatic, and colorectal cancers. The trial has two parts: the first part will find the best dose of the drug, and the second part will involve more participants to learn more about how well it works. The study will last for about four years and is open to people aged 65 to 74, regardless of gender.

To participate, individuals must have one of the specific types of cancer mentioned and meet certain health criteria. For example, those with serious heart issues or uncontrolled infections cannot join. Participants will receive the study drug and will be monitored closely for side effects and effectiveness. It’s important to know that this trial is currently recruiting, which means they are looking for volunteers to take part. If you or someone you know is interested, discussing it with a healthcare provider can help determine if it’s a good option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Have one of the following solid tumor cancers:
• • Cohort A1: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic, and colorectal cancer (CRC)
• • Cohort A2/A3/A4/A5/B1/B2: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer
• • Cohort C1/C2: Endometrial cancer, cervical cancer, NSCLC, TNBC, CRC or pancreatic cancer
• Exclusion Criteria:
• • Individual with known or suspected uncontrolled central nervous system (CNS) metastases
• • Individual with history of carcinomatous meningitis
• • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
• • Individual with evidence of corneal keratopathy or history of corneal transplant
• • Any serious unresolved toxicities from prior therapy
• • Significant cardiovascular disease
• • Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
• • History of pneumonitis/interstitial lung disease
• • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention